ADVFN US – Market Content Editor
-
Infosys Q2 results meet earnings forecasts while revenue exceeds expectations
Infosys Limited (NYSE:INFY), the global leader in digital services and consulting, reported second-quarter earnings in line with analyst estimates, while revenue outperformed projections, leading to a modest 0.2% increase in its share price after the announcement. The company posted earnings per share of $0.19 for the quarter, matching the consensus forecast. Revenue reached $4.94 billion,…
-
First Busey shares climb after Q2 earnings surpass forecasts
Shares of First Busey Corporation (NASDAQ:BUSE) rose 2.9% following the regional bank’s announcement of second-quarter earnings that beat analyst projections, largely driven by strong revenue growth after acquiring CrossFirst Bankshares (NASDAQ:CFB). The bank reported adjusted earnings of $0.63 per share, exceeding the $0.60 consensus estimate. Revenue reached $198.05 million, topping the forecasted $193.73 million and…
-
Amphenol shares climb 6% on robust IT datacom-driven Q2 results
Amphenol Corporation (NYSE:APH) saw its shares rise 6% after reporting second-quarter earnings that far surpassed analyst predictions, fueled by outstanding growth in its IT datacom segment. The company posted adjusted earnings per share of $0.81, outperforming the estimated $0.66 by 23%. Revenue surged to $5.7 billion, marking a 57% year-over-year increase and well exceeding the…
-
Anebulo Pharmaceuticals shares surge 80% after board approves plan to go private
Shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) jumped 80% following the company’s announcement that its Board of Directors has approved a plan to take the clinical-stage pharmaceutical firm private through a reverse stock split, which would end its status as a public SEC reporting company. The company intends to execute a reverse stock split at a ratio…
-
Johnson & Johnson’s Darzalex approved in EU for high-risk smouldering myeloma
Johnson & Johnson (NYSE:JNJ) announced Wednesday that the European Commission has granted approval for its Darzalex subcutaneous formulation to be used as a monotherapy for adults diagnosed with high-risk smouldering multiple myeloma. This approval represents the first treatment option available for this patient group, addressing a significant unmet need in managing the asymptomatic, intermediate stage…
-
Freeport-McMoRan surpasses Q2 expectations with boosted copper sales
Freeport-McMoRan (NYSE:FCX) delivered second-quarter earnings and revenue results that outpaced Wall Street forecasts, driven by increased copper production and sales. Despite this, the company’s shares slipped 1% in premarket trading. The U.S.-based mining giant reported adjusted earnings of $0.54 per share, exceeding the average analyst estimate of $0.45. Revenue climbed to $7.58 billion from $5.74…
-
Lamb Weston shares jump 6% following strong Q4 earnings and cost-saving plan
Lamb Weston Holdings Inc. (NYSE:LW) saw its stock rise 6% after surpassing expectations for the fourth quarter and unveiling an ambitious strategy to achieve at least $250 million in savings. The company posted adjusted earnings of $0.87 per share for its fiscal Q4, well above analyst estimates of $0.64. Revenue grew 4% year-over-year to $1.68…
-
Oklo shares climb following strategic partnership with Liberty Energy
Oklo Inc. (NYSE:OKLO) saw its stock increase by 3% in early trading after unveiling a strategic collaboration with Liberty Energy Inc. (NYSE:LBRT) to create integrated power solutions tailored for customers with high energy demands. The alliance focuses on providing comprehensive power solutions by combining Liberty’s natural gas generation capabilities with Oklo’s cutting-edge nuclear technology. Initially,…
-
Apple unveils AppleCare One, an insurance plan covering up to three devices
Apple Inc. (NASDAQ:AAPL) announced the launch of AppleCare One, a new subscription insurance service that protects up to three devices for $20 per month. The plan includes battery replacements, 24/7 customer support, and coverage for accidental damage such as drops and spills. Customers wishing to add more devices beyond the initial three can do so…
-
Precision BioSciences shares climb after FDA grants orphan drug status
Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for Duchenne muscular dystrophy (DMD). The clinical-stage gene editing company, which uses its proprietary ARCUS platform, earned the designation for its potential to treat DMD, a rare genetic…